...
首页> 外文期刊>Modern Rheumatology >Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan
【24h】

Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan

机译:在日本的一项大型观察性队列研究IORRA中,从2000年至2006年改善了类风湿关节炎患者的疾病活动

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to show whether the disease activity of rheumatoid arthritis (RA) patients had improved in Japan, and whether the improvement of disease activity had resulted in a better outcome of patients. In a single-institute-based prospective observational cohort of RA patients (Institute of Rheumatology, Rheumatoid Arthritis, IORRA), a total of 7512 patients were enrolled, and their information was collected biannually. A cross-sectional data set A that included all patients in each phase was analyzed. From October 2000 to April 2006, disease activity score DAS28 significantly improved from 4.15 to 3.63, and the frequency of patients in remission (DAS28 < 2.6) increased from 8.5% to 21.5%. During this period, the frequency of methotrexate users increased from 33.9% to 58.7% and the average dosage of methotrexate also increased from 5.59 mg/week to 6.94 mg/week; on the other hand, there was no increase in any adverse reaction among the methotrexate users. To investigate the relationship between longitudinal disease control and progression of disability, a longitudinal data set B that included 712 patients who completed all phases of the study from 2000 to 2006 was selected and was analyzed. The disability index JHAQ of a poorly controlled group (average DAS > 5.1) increased (+34.8%), that of a moderately controlled group (average DAS 3.2–5.1) also increased (+14.0%), but that of a well-controlled group (average DAS < 3.2) decreased (–13.0%). In conclusion, by using a prospective observational cohort IORRA in Japan, we demonstrate that RA disease activity improved from 2000 to 2006, which correlates with an increased use of methotrexate. The suppression of disease activity resulted in a better outcome for patients.
机译:这项研究的目的是显示日本的类风湿关节炎(RA)患者的疾病活动是否有所改善,以及疾病活动的改善是否导致患者的预后更好。在基于单机构的RA患者的前瞻性观察队列中(风湿病学会,类风湿关节炎,IORRA),共有7512名患者入组,并且每半年收集一次他们的信息。分析包括每个阶段的所有患者的横截面数据集A。从2000年10月到2006年4月,疾病活动性DAS28评分从4.15显着提高到3.63,缓解的患者频率(DAS28 <2.6)从8.5%增加到21.5%。在此期间,甲氨蝶呤使用者的频率从33.9%增加到58.7%,甲氨蝶呤的平均剂量也从5.59毫克/周增加到6.94毫克/周;另一方面,甲氨蝶呤使用者之间的不良反应没有增加。为了研究纵向疾病控制与残疾进展之间的关系,选择并分析了纵向数据集B,该数据集包括712名完成研究从2000年至2006年的所有患者。不良控制组(平均DAS> 5.1)的残疾指数JHAQ增加(+ 34.8%),中度控制组(平均DAS 3.2-5.1)的残疾指数JHAQ也增加(+ 14.0%),而控制良好的组组(平均DAS <3.2)下降(–13.0%)。总之,通过在日本使用前瞻性观察队列IORRA,我们证明了从2000年到2006年RA疾病活动有所改善,这与甲氨蝶呤的使用增加有关。疾病活动的抑制为患者带来了更好的结果。

著录项

  • 来源
    《Modern Rheumatology》 |2007年第4期|283-289|共7页
  • 作者单位

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford CA USA;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

    Institute of Rheumatology Tokyo Women''s Medical University 10-22 Kawada-cho Shinjuku-ku Tokyo 162-0054 Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Cohort study; DAS28; Disability; Methotrexate; Rheumatoid arthritis;

    机译:队列研究;DAS28;残疾;甲氨蝶呤;类风湿关节炎;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号